News
Montana Bioscience Alliance Fall 2023 Newsletter
October 17, 2023 /
New Diagnostic Tests Could Change The Landscape For Leukemia Prevention And Treatment
Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004
Solo-Dex Nominated for Prestigious 2023 Prix Galien USA Awards
MATR Supporters (view all)
Posted in: Montana Bioscience Cluster Initiative, Montana Business, Montana Business and Govt. Agency Collaboration Success, Montana Ambassadors, Developing a more Entrepreneurial Montana, Biotech, Funding and Building your Business, Regional Economic Development, Regional Business News, Non-Profit News, Montana Leadership